Mirae Asset Global Investments Co. Ltd. Has $603,000 Holdings in Viridian Therapeutics, Inc. (NASDAQ:VRDN)

Mirae Asset Global Investments Co. Ltd. lessened its holdings in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN) by 5.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 27,687 shares of the company’s stock after selling 1,540 shares during the quarter. Mirae Asset Global Investments Co. Ltd.’s holdings in Viridian Therapeutics were worth $603,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently bought and sold shares of VRDN. SG Americas Securities LLC increased its position in Viridian Therapeutics by 150.5% during the third quarter. SG Americas Securities LLC now owns 102,667 shares of the company’s stock worth $1,575,000 after buying an additional 61,676 shares during the last quarter. Raymond James & Associates increased its position in Viridian Therapeutics by 71.1% during the third quarter. Raymond James & Associates now owns 15,164 shares of the company’s stock worth $233,000 after buying an additional 6,303 shares during the last quarter. Hennion & Walsh Asset Management Inc. increased its position in Viridian Therapeutics by 89.5% during the third quarter. Hennion & Walsh Asset Management Inc. now owns 27,112 shares of the company’s stock worth $416,000 after buying an additional 12,807 shares during the last quarter. Knights of Columbus Asset Advisors LLC increased its position in Viridian Therapeutics by 2.9% during the third quarter. Knights of Columbus Asset Advisors LLC now owns 29,553 shares of the company’s stock worth $453,000 after buying an additional 823 shares during the last quarter. Finally, Jump Financial LLC increased its position in Viridian Therapeutics by 25.7% during the third quarter. Jump Financial LLC now owns 61,654 shares of the company’s stock worth $946,000 after buying an additional 12,623 shares during the last quarter.

Viridian Therapeutics Trading Down 2.5 %

Shares of VRDN stock opened at $12.70 on Friday. The company has a current ratio of 18.26, a quick ratio of 18.26 and a debt-to-equity ratio of 0.09. The stock has a market cap of $797.18 million, a P/E ratio of -2.39 and a beta of 1.07. The stock has a 50 day simple moving average of $17.29 and a 200 day simple moving average of $17.49. Viridian Therapeutics, Inc. has a 1 year low of $10.93 and a 1 year high of $28.99.

Viridian Therapeutics (NASDAQ:VRDN) last released its earnings results on Tuesday, February 27th. The company reported ($1.35) earnings per share for the quarter, missing the consensus estimate of ($0.98) by ($0.37). Viridian Therapeutics had a negative return on equity of 121.80% and a negative net margin of 75,711.48%. The business had revenue of $0.07 million for the quarter, compared to the consensus estimate of $0.15 million. During the same quarter in the previous year, the company earned ($1.13) earnings per share. The firm’s revenue for the quarter was down 31.4% on a year-over-year basis. On average, research analysts predict that Viridian Therapeutics, Inc. will post -4.39 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts have weighed in on the company. Needham & Company LLC reissued a “buy” rating and set a $30.00 price target on shares of Viridian Therapeutics in a research report on Wednesday, March 20th. B. Riley decreased their target price on Viridian Therapeutics from $29.00 to $25.00 and set a “buy” rating on the stock in a research report on Thursday, March 21st. HC Wainwright reaffirmed a “buy” rating and issued a $37.00 target price on shares of Viridian Therapeutics in a research report on Thursday, February 29th. Finally, Wedbush upped their target price on Viridian Therapeutics from $39.00 to $40.00 and gave the company an “outperform” rating in a research report on Wednesday, February 28th. Ten research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $36.60.

Viridian Therapeutics Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.